Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSM8 | ISIN: US87978U1088 | Ticker-Symbol: 3OS
Tradegate
23.05.24
09:50 Uhr
2,994 Euro
-0,024
-0,80 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,9963,04417:08
2,9963,04417:08

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.05.Tempest Therapeutics Inc reports results for the quarter ended in March - Earnings Summary6
09.05.Tempest Therapeutics: Tempest Reports First Quarter 2024 Financial Results and Provides Business Update86Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual MeetingPublished...
► Artikel lesen
09.05.Tempest Therapeutics, Inc. - 10-Q, Quarterly Report1
09.05.Tempest Therapeutics, Inc. - 8-K, Current Report1
26.04.Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)124BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
09.04.Tempest Therapeutics: Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting12
04.04.Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications165TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...
► Artikel lesen
20.03.Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary20
19.03.Tempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
19.03.Tempest Therapeutics GAAP EPS of -$1.91 beats by $0.033
19.03.Tempest Therapeutics, Inc. - 10-K, Annual Report1
19.03.Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update134Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...
► Artikel lesen
19.03.Tempest Therapeutics, Inc. - 8-K, Current Report2
05.03.Tempest Therapeutics: Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting21
02.02.Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)442BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
► Artikel lesen
05.01.Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)264BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
► Artikel lesen
01.12.23Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)707BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
► Artikel lesen
08.11.23Tempest Therapeutics: Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update335TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC studyNew capital strengthens balance sheet and extends cash runway into...
► Artikel lesen
13.10.23Pre-market Movers: T2 Biosystems, Outset Medical, Tempest Therapeutics, Cassava Sciences, SMART Global Holdings1.557BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.20 A.M. ET).In the Green Scienjoy Holding Corporation (SJ) is up over 11% at...
► Artikel lesen
12.10.23Pre-market Movers: OpGen, Tempest Therapeutics, FAT Brands, MAIA Biotechnology, Tupperware Brands1.022OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.05 A.M. ET).In the Green OpGen, Inc. (OPGN) is up over 667% at $2.58. MAIA...
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8